Artiva Biotherapeutics, founded with a mission to advance cancer treatment, focuses on developing allogeneic natural killer (NK) cell therapies and chimeric antigen receptor NK (CAR-NK) therapies. The company aims to provide innovative solutions for both blood cancers and solid tumors. By leveraging cutting-edge biotechnology, Artiva seeks to offer effective and scalable immunotherapy options that can be readily available to patients in need.
Notable figures affiliated with Artiva include Neha Krishnamohan, who serves as CFO and EVP of Corporate Development, and Jennifer Bush, the Chief Operating Officer. The company has achieved significant milestones, such as dosing the first patient in a Phase trial of their AlloNK® cell therapy candidate for lupus nephritis. Artiva's advancements in NK cell therapies have positioned it as a key player in the biotech industry, contributing to the broader impact on cancer treatment and immunotherapy.
